Transdermal fentanyl represents a cornerstone pharmacotherapeutic option for managing moderate to severe chronic pain in carefully selected, opioid-tolerant patients. This synthetic opioid agonist, approximately 100 times more potent than morphine, exploits its low molecular weight and high lipophilicity to achieve sustained systemic delivery through the skin, bypassing first-pass hepatic metabolism and attaining approximately 90% bioavailability. The present article provides a comprehensive overview of transdermal fentanyl’s FDA-approved indications—strictly limited to chronic non-cancer and cancer-associated pain requiring continuous analgesia in patients already tolerant to opioids—while explicitly excluding its prior use in acute postoperative settings due to historical safety concerns. The mechanism of action centers on high-affinity agonism at μ-opioid receptors within central pain-modulating pathways, though clinically significant effects also occur at δ and κ receptors. Pharmacokinetically, the transdermal system creates a cutaneous reservoir, delaying therapeutic plasma levels until 12 to 16 hours after initial application but enabling steady-state control for 72 hours per patch. Adverse effects follow the typical opioid profile, with nausea, vomiting, and constipation being most common; however, comparative evidence suggests a roughly 30% lower incidence of constipation and sedation relative to sustained-release oral morphine. Critically, respiratory depression remains the most concerning toxicity, particularly in opioid-naïve individuals, which underpins the absolute contraindication for non-tolerant patients and those with acute or unstable respiratory conditions. Effective monitoring requires attention to CYP3A4-mediated drug interactions, proper patch application and rotation, and secure disposal of used patches that may retain substantial residual drug content. Successful outcomes depend upon interprofessional collaboration among physicians, nurses, pharmacists, and advanced practice providers, emphasizing patient selection, gradual dose titration, withdrawal recognition, and ready access to naloxone for toxicity reversal.